Logo image of GKOS

GLAUKOS CORP (GKOS) Stock Fundamental Analysis

NYSE:GKOS - US3773221029 - Common Stock

90.71 USD
-3.23 (-3.44%)
Last: 9/9/2025, 3:07:24 PM
Fundamental Rating

4

GKOS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GKOS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GKOS has reported negative net income.
In the past year GKOS has reported a negative cash flow from operations.
In the past 5 years GKOS always reported negative net income.
In the past 5 years GKOS reported 4 times negative operating cash flow.
GKOS Yearly Net Income VS EBIT VS OCF VS FCFGKOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of GKOS (-9.40%) is better than 62.63% of its industry peers.
GKOS has a better Return On Equity (-12.13%) than 65.26% of its industry peers.
Industry RankSector Rank
ROA -9.4%
ROE -12.13%
ROIC N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
GKOS Yearly ROA, ROE, ROICGKOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

GKOS has a better Gross Margin (76.34%) than 88.95% of its industry peers.
In the last couple of years the Gross Margin of GKOS has declined.
The Profit Margin and Operating Margin are not available for GKOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
GKOS Yearly Profit, Operating, Gross MarginsGKOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GKOS has been increased compared to 1 year ago.
GKOS has more shares outstanding than it did 5 years ago.
GKOS has a better debt/assets ratio than last year.
GKOS Yearly Shares OutstandingGKOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GKOS Yearly Total Debt VS Total AssetsGKOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

GKOS has an Altman-Z score of 13.78. This indicates that GKOS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.78, GKOS belongs to the top of the industry, outperforming 93.68% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that GKOS is not too dependend on debt financing.
The Debt to Equity ratio of GKOS (0.09) is better than 63.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 13.78
ROIC/WACCN/A
WACC8.47%
GKOS Yearly LT Debt VS Equity VS FCFGKOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.51 indicates that GKOS has no problem at all paying its short term obligations.
The Current ratio of GKOS (5.51) is better than 79.47% of its industry peers.
GKOS has a Quick Ratio of 4.69. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.
GKOS has a better Quick ratio (4.69) than 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.51
Quick Ratio 4.69
GKOS Yearly Current Assets VS Current LiabilitesGKOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.49% over the past year.
GKOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.70%.
The Revenue has been growing by 10.10% on average over the past years. This is quite good.
EPS 1Y (TTM)51.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)26.7%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%29.71%

3.2 Future

GKOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.04% yearly.
The Revenue is expected to grow by 26.93% on average over the next years. This is a very strong growth
EPS Next Y52.04%
EPS Next 2Y41.9%
EPS Next 3Y36.68%
EPS Next 5Y29.04%
Revenue Next Year27.84%
Revenue Next 2Y26.74%
Revenue Next 3Y25.76%
Revenue Next 5Y26.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GKOS Yearly Revenue VS EstimatesGKOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GKOS Yearly EPS VS EstimatesGKOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GKOS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 3491.61, GKOS can be considered very expensive at the moment.
66.32% of the companies in the same industry are more expensive than GKOS, based on the Price/Forward Earnings ratio.
GKOS is valuated expensively when we compare the Price/Forward Earnings ratio to 22.66, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 3491.61
GKOS Price Earnings VS Forward Price EarningsGKOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 1K 2K 3K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GKOS Per share dataGKOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GKOS does not grow enough to justify the current Price/Earnings ratio.
GKOS's earnings are expected to grow with 36.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.9%
EPS Next 3Y36.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GKOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLAUKOS CORP

NYSE:GKOS (9/9/2025, 3:07:24 PM)

90.71

-3.23 (-3.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners102.52%
Inst Owner Change4.91%
Ins Owners3.32%
Ins Owner Change1.69%
Market Cap5.20B
Analysts82.86
Price Target125.97 (38.87%)
Short Float %6.47%
Short Ratio3.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.51%
Min EPS beat(2)11.08%
Max EPS beat(2)37.95%
EPS beat(4)3
Avg EPS beat(4)22.32%
Min EPS beat(4)-2.27%
Max EPS beat(4)42.53%
EPS beat(8)5
Avg EPS beat(8)8.64%
EPS beat(12)8
Avg EPS beat(12)7.63%
EPS beat(16)11
Avg EPS beat(16)4.11%
Revenue beat(2)2
Avg Revenue beat(2)3.68%
Min Revenue beat(2)2.01%
Max Revenue beat(2)5.35%
Revenue beat(4)4
Avg Revenue beat(4)3.41%
Min Revenue beat(4)2.01%
Max Revenue beat(4)5.35%
Revenue beat(8)8
Avg Revenue beat(8)3.55%
Revenue beat(12)12
Avg Revenue beat(12)3.87%
Revenue beat(16)16
Avg Revenue beat(16)4.23%
PT rev (1m)0%
PT rev (3m)-4.26%
EPS NQ rev (1m)-2.29%
EPS NQ rev (3m)-15.66%
EPS NY rev (1m)-6.14%
EPS NY rev (3m)-4.74%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)0.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3491.61
P/S 12.02
P/FCF N/A
P/OCF N/A
P/B 6.8
P/tB 12.16
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)0.03
Fwd EY0.03%
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS7.55
BVpS13.34
TBVpS7.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.4%
ROE -12.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.34%
FCFM N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.95%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.51
Quick Ratio 4.69
Altman-Z 13.78
F-Score5
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)54.99%
Cap/Depr(5y)69.95%
Cap/Sales(3y)6.26%
Cap/Sales(5y)7.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y52.04%
EPS Next 2Y41.9%
EPS Next 3Y36.68%
EPS Next 5Y29.04%
Revenue 1Y (TTM)26.7%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%29.71%
Revenue Next Year27.84%
Revenue Next 2Y26.74%
Revenue Next 3Y25.76%
Revenue Next 5Y26.93%
EBIT growth 1Y19.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.06%
EBIT Next 3Y44.76%
EBIT Next 5Y43.81%
FCF growth 1Y54.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.36%
OCF growth 3YN/A
OCF growth 5YN/A